Source comparison
Thymosin Alpha-1 Help Hashimoto's Research: Comparison
Thymosin Alpha-1 TLR2 agonist. Upregulates Tregs, suppresses Th1 cytokines 25–35% (preclinical), 28–34% (limited human trials) Adjunctive immune modulation in early-moderate disease Promising mechanism with insufficient long-term human validation. Not a first-
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR2 agonist. Upregulates Tregs, suppresses Th1 cytokines
- 25–35% (preclinical), 28–34% (limited human trials)
- Adjunctive immune modulation in early-moderate disease
- Promising mechanism with insufficient long-term human validation. Not a first-line therapy
- Selenium Supplementation
- Glutathione peroxidase cofactor. Reduces oxidative stress in thyroid tissue
- 10–21% (meta-analysis of 6 RCTs)
- Adjunctive nutrient therapy, particularly in selenium-deficient populations
- Modest benefit, well-tolerated, limited to patients with baseline selenium deficiency
- Low-Dose Naltrexone (LDN)
- Opioid receptor antagonist. Modulates immune activation via endorphin pathways
- 15–25% (case series and small trials)
- Off-label immune modulation in autoimmune thyroiditis
- Widely used but lacks Phase III trial validation. Effect size similar to thymosin alpha-1
- Standard Levothyroxine Monotherapy
- Thyroid hormone replacement
- 5–12% (natural fluctuation over 6–12 months)
- First-line treatment for hypothyroidism
- Addresses hormone deficiency but does not target autoimmune pathology